Galena: USPTO Approves Patent Application For GALE-401 Composition Of Matter

(RTTNews) - Galena Biopharma Inc. (GALE) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application for GALE-401 composition of matter. GALE-401 is a controlled release formulation of anagrelide for use in reducing platelet counts in patients with Myeloproliferative Neoplasms. The patent will expire in 2029, not including any patent term extensions.

The claims cover controlled release formulations of GALE-401 in a broad range of unit dosage forms, articles of manufacture containing GALE-401, and methods of reducing platelet counts in patients with a broad spectrum of diseases and conditions, including MPNs, by administering GALE-401.